Related Experiment Video
Updated: May 14, 2026

Isolation of Brain-infiltrating Leukocytes
Published on: June 13, 2011
Progressive multifocal leukoencephalopathy in an immunocompetent patient
Panos G Christakis1, Daniel Okin, Anita J Huttner
1Yale School of Medicine, New Haven, Connecticut, United States.
Abstract:
A 69-year old man presents with a subacute history of worsening confusion, anxiety and abnormal gait. Brain MRI revealed an extensive non-enhancing signal abnormality of parieto-occipito-temporal white matter. CSF PCR was positive for JC virus, suggestive of progressive multifocal leukoencephalopathy (PML). Extensive workup for occult immunosuppression was negative. Although PML in an immunocompetent patient is exceedingly rare, biopsy confirmed the diagnosis. Mirtazapine and mefloquine therapies were initiated and JCV DNA titre decreased by 100-fold at six months. One year later, his clinical course had stabilized and neuroimaging was improved. Our case suggests that PML can rarely afflict immunocompetent individuals and that serotonin receptor targeting pharmacological therapy may improve the outcome.
Insights
Progressive multifocal leukoencephalopathy (PML) is rare in immunocompetent individuals. This case highlights a potential treatment approach using serotonin receptor targeting therapy, showing promising results in stabilizing the patient's condition.
Area of Science:
- Neuroimmunology
- Viral Neurology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the central nervous system.
- PML is typically associated with profound cellular immunodeficiency.
- JC virus (JCV) is the causative agent of PML.
Observation:
- A 69-year-old immunocompetent male presented with subacute confusion, anxiety, and gait disturbance.
- Brain MRI showed extensive white matter abnormalities in the parieto-occipito-temporal regions.
- Cerebrospinal fluid (CSF) PCR confirmed JCV positivity, leading to a diagnosis of PML.
Findings:
- Despite being immunocompetent, the patient's PML diagnosis was confirmed via biopsy.
- Initiation of mirtazapine and mefloquine led to a 100-fold decrease in JCV DNA titre within six months.
- Clinical stabilization and neuroimaging improvement were observed one year post-treatment.
Implications:
- This case suggests PML can occur in immunocompetent individuals, challenging typical etiological assumptions.
- Serotonin receptor targeting therapy (mirtazapine) may represent a novel therapeutic strategy for PML.
- Further research is warranted to explore the efficacy of pharmacological interventions in PML management.
Related Concept Videos
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Multiple Sclerosis l: Introduction
Brain Abscess l: Introduction
Cytomegalovirus Disease
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...